Advanced Medical Isotope Corporation (trading symbol QB:ADMD)
1021 N. Kellogg St. Kennewick, Washington 99336 US
T: 509.736.4000 F: 509.736.4007 E: info@isotopeworld.com

Tags

Latest News

Advanced Medical Isotope CEO Releases Shareholder Letter Outlining New Streamlined Path to FDA Submission

(Tue, 14, Feb 2017) >> read more

 

Advanced Medical Isotope CEO Issues Letter to Shareholders Issues Full Status Update, Planned FDA Submission Pathway and Business Plan for 2017 and Beyond

(Wed, 11, Jan 2017) >> read more

 

Advanced Medical Isotope announced today that Dr. Michael Korenko, Ph. D., who formerly served as an advisor to the Board, was named as AMI's interim President and Chief Executive Officer, replacing James Katzaroff.

(Tue, 20, Dec 2016) >> read more

 

Advanced Medical Isotope announced today that it has been awarded in the Superior Court of the State of Washington in and for Benton County, a total judgment of $527,875.74 USD. 
(Fri, 2, Dec 2016) >> read more

 

 Click here for more news and updates

Social Media


Fri

02

Dec

2016

Advanced Medical Isotope Wins Default Judgment of $527,875.74

KENNEWICK, WA / ACCESSWIRE / December 2, 2016 / Advanced Medical Isotope Corporation ("AMI") (OTC: ADMD), a late stage radiation oncology focused medical device company, announced today that it has been awarded in the Superior Court of the State of Washington in and for Benton County, a total judgment of five-hundred-twenty-seven-thousand-eight-hundred-seventy-five-dollars and seventy-four cents ($527,875.74 USD), with interest accruing at the rate of twelve-percent (12%) until paid in full against BancLeasing, Inc.

 

The interpretation and application of the terms for finance leases from BancLeasing, Inc. to AMI for laboratory equipment, a linear accelerator, and tenant improvements have been contested by AMI since early in the contract. After failed attempts to settle the matter out of court, AMI filed a lawsuit and was recently awarded default judgment.

 

AMI Chief Financial Officer L. Bruce Jolliff stated:

 

"The Company is actively pursuing collection efforts, and while we can give no assurance as to the final amount and when we might collect, AMI will utilize every avenue possible to collect on this judgment."

 

About Advanced Medical Isotope Corporation

 

Advanced Medical Isotope Corporation (ADMD) is a late stage radiation oncology focused medical device company engaged in the development of yttrium-90 based brachytherapy devices for the treatment of non resectable tumors. The IsoPet Solutions division is focused on establishing the infrastructure necessary to provide product to veterinary clinics including regulatory clearances and compliance as well as providing product awareness and education to veterinary oncologists. Brachytherapy uses radiation to destroy cancerous tumors by placing a radioactive isotope inside or next to the treatment area. The Company intends to outsource material aspects of manufacturing, distribution, sales and marketing for its products in the United States and to enter into licensing arrangements outside of the United States, though the Company will evaluate its alternatives before finalizing its plans. For more information, please visit our websites: www.isopetsolutions.com and www.isotopeworld.com.

 

Safe Harbor Statement

 

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by the use of the words "may," "will," "should," "plans," "expects," "anticipates," "continue," "estimates," "projects," "intends," and similar expressions. Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, the Company's ability to successfully execute its expanded business strategy, including by entering into definitive agreements with suppliers, commercial partners and customers; general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technical advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, regulatory requirements and the ability to meet them, government agency rules and changes, and various other factors beyond the Company's control.

 

 

CONTACT:

  

Company Contact:

 

Advanced Medical Isotope Corporation

James C. Katzaroff, CEO

1021 N Kellogg 

Kennewick WA 99336

509-736-4000

 

Investors:

Circadian Group IR

Tyler Troup, B. Comm

info@Circadian-group.com

877-950-8300

 

SOURCE: Advanced Medical Isotope Corporation